Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

US Market Report for Rheumatoid Arthritis Immunology Drugs 2018 - Unit Sales, ASPs, Market Value & Growth Trends - Research and Markets

Research and Markets
Posted on: 02 Nov 17

The "US Market Report for Rheumatoid Arthritis Immunology Drugs 2018 - MedCore" report has been added to Research and Markets' offering.

Current treatments of RA aim to relieve the symptoms of the disease and regain the maximum functionality of the damaged joint. There is no cure for rheumatoid arthritis. The initial treatment option is disease-modifying antirheumatic drugs, also known as DMARDs.

DMARDs are a group of medications commonly used in patients with rheumatoid arthritis. Some of these drugs are also used in treating other conditions such as ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus. DMARDs work to reduce pain and inflammation, to prevent or minimize joint damage. They take effect over months and are not designed to provide immediate relief of symptoms.

DMARDs can be prescribed along with nonsteroidal anti-inflammatory drugs and/or low-dose corticosteroids. Common DMARDs include methotrexate (Rheumatrex, Trexall, Otrexup, and Rasuvo), leflunomide (Arava), hydroxychloroquine (Plaquenil) and sulfasalazine (Azulfidine).

Patients in more severe stages of the disease may need biologic response modifiers. These medications can block immune system chemical signals that lead to inflammation and joint damage. The biologic drugs include ORENCIA (abatacept), HUMIRA (adalimumab), Kineret (Anakinra), CIMZIA (certolizumab), ENBREL (etanercept), SIMPONI (golimumab), REMICADE (infliximab), Rituxan and MabThera (rituximab) and Actemra (tocilizumab).

Key Topics Covered:

Executive Summary

1. Version History

2. 9-Step Methodology

3. Mechanism of Action

4. Product Assessment

5. Country Profile

6. Rheumatoid Arthritis Market

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceuticals
  • UCB S.A.

For more information about this report visit

View source version on

Business Wire

Last updated on: 02/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.